TY  - CONF

T1  - Cost effectiveness of adalimumab (HUMIRA (TM), Abbott) in the treatment of patients with moderate to severe rheumatoid arthritis (RA)

JO  - ARTHRITIS AND RHEUMATISM

PY  - 2003/09/01

AU  - Bansback NJ

AU  - Brennan A

AU  - Sengupta N

AU  - Chang KY

ED  - 

VL  - 48

IS  - 9

SP  - S215

EP  - S215

Y2  - 2024/12/22

ER  -